CAS: 1191-50-0; Sodium Tetradecyl Sulfate

该化合物是化学配方C14H29NaO4S的阴离子表面活性剂.其特点是14碳烷基链,具有很强的疏水特性,而硫酸盐组则确保水溶性和地表活动高.STS在生物化学和工业应用中广泛使用,包括电磷酸蛋白衰减和制剂中的乳化剂或湿剂.其临界小鼠浓度和稳定性使其适合精确的实验室使用.该化合物在减少表面紧张和形成小鼠方面显示出可靠的性能,确保研究和制造过程取得一致的结果.

结构式图片

相似化合物

151-21-3 151-21-3 1120-04-3

欧盟法规

ECHA物质ECHA物质C&L通报REACH预注册

上下游产品

1-Tetradecanol1-myristyl glycerol

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-8236960-B2
    优先权日:2004-09-27
    标 题 :Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms
    发明人:THYGESEN MIKKEL BOAS; SCHLIENGER NATHALIE; TOLF BO-RAGNAR; ANDERSSON CARL-MAGNUS A; BLATTER FRITZ; BERGHAUSEN JOERG
    权利人:THYGESEN MIKKEL BOAS; SCHLIENGER NATHALIE; TOLF BO-RAGNAR; ANDERSSON CARL-MAGNUS A; BLATTER FRITZ; BERGHAUSEN JOERG; ACADIA PHARM INC
    摘要:Disclosed herein are methods for synthesizing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl) -N′-(4-(2-methylpropyloxy)-phenylmethyl)carbamide. Also disclosed herein is the hemi-tartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2 -methylpropyloxy)-phenylmethyl)carbamide and methods for obtaining the salt. Further disclosed are various crystalline forms of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)-phenylmethyl)carbamide and its hemi-tartrate salt including various polymorphs and solvates.

    专利号:US-2004030209-A1
    优先权日:2000-11-30
    标 题:Method for the production of alkyl aryl sulphonates
    发明人:NARBESHUBER THOMAS; STEINBRENNER ULRICH; KRACK GERHARD
    摘要:The preparation of alkylaryl compounds takes place by n 1) preparation of a mixture of, on statistical average, predominantly monobranched C 10-14 -olefins by n a) reaction of a C 4 -olefin mixture over a metathesis catalyst for the preparation of an olefin mixture comprising 2-pentene and/or 3-hexene, and optional removal of 2-pentene and/or 3-hexene, followed by dimerization of the resulting 2-pentene and/or 3-hexene over a dimerization catalyst to give a mixture comprising C 10-12 -olefins, and optionally removal of the C 10-12 -olefins, or n b) extraction of predominantly monobranched paraffins from kerosene cuts and subsequent dehydrogenation, or n c) Fischer-Tropsch synthesis of olefins or paraffins, where the paraffins are dehydrogenated, or n d) dimerization of shorter-chain internal olefins, or n e) isomerization of linear olefins or paraffins, where the isomerized paraffins are dehydrogenated, n 2) reaction of the olefin mixture obtained in stage 1) with an aromatic hydrocarbon in the presence of an alkylation catalyst which contains zeolites of the faujasite type.

    专利号:US-2024325572-A1
    优先权日:2021-07-15
    标 题 :N-heterocyclyl substituted 2-cyano-3-(naphthalen-2-yl)acrylamide derivatives as fluorophors for detection of amyloid and amyloid-like proteins for diagnosis of neurodegenerative disorders
    发明人:SARRAF STELLA T
    权利人:AMYDIS INC
    摘要:Provided herein is the design and synthesis of novel molecular rotor fluorophores of formula I useful for detection of amyloid or amyloid like proteins. The fluorophores are designed to exhibit enhanced fluorescence emission upon associating with amyloid or amyloid like proteins as compared to unbound compound. Also disclosed herein are the compounds for use in methods for diagnosis and treatment of diseases associated with an amyloid or amyloid like proteins, such as e.g. Alzheimer's disease or traumatic brain injury (TBI), Parkinson's disease, vascular dementia, amyotrophic lateral sclerosis, Down syndrome, traumatic brain injury, chronic traumatic encephalopathy, schizophrenia or depression. Exemplary compounds are e.g. N-heterocyclyl substituted 2-cyano-3-(naphthalen-2-yl)acrylamide derivatives, such as e.g. (E)-2-cyano-N-(2-(2-hydroxy)ethoxy)ethyl)-3-(6-(pyrrolidin-1-yl)naphthalen-2-yl) acrylamide (example 1): Experimental data on in-vitro binding studies with amyloid beta is provided.

    专利号:US-7790899-B2
    优先权日:2004-09-27
    标 题 :Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
    发明人:TOLF BO-RAGNAR; SCHLIENGER NATHALIE; THYGESEN MIKKEL BOAS
    权利人:ACADIA PHARM INC
    摘要:Disclosed herein are methods for synthesizing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide. Also disclosed herein is the hemi-tartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)-phenylmethyl)carbamide and methods for obtaining the salt. Further disclosed are various crystalline forms of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its hemi-tartrate salt including various polymorphs and solvates.

    专利号:WO-2022223696-A1
    优先权日:2021-04-22
    标 题 :Process for synthesis of n-alkyl-n-phenyl hydrazine
    发明人:ENDRES ANDREAS; NANDURKAR NITIN SUBHASH; KATE KIRAN; SATHE SHANTANU SHRIKANT
    权利人:COLORANTS INT LTD
    摘要:The invention provides a process for synthesizing N-alkyl-N-phenyl hydrazine which is devoid of any organic solvents and can be carried out at lower temperatures. The process is environmental-friendly and gives better yield and high purity of the N-alkyl-N-phenyl hydrazine.

    专利号:US-2006062846-A1
    优先权日:2004-09-17
    标题 :Alfuzosin tablets and synthesis
    发明人:SCHEER MATHIAS; REY HELENE; FISCHER MARC; KRAMER DIRK
    权利人:CIMEX PHARMA AG
    摘要:A monolithic composition includes alfuzosin in a polymeric matrix adapted to release 13-33% of the alfuzosin within 2 hours, 40-60% of the alfuzosin within 7 hours, and greater than 80% of the alfuzosin within 20 hours of administration. A unit dosage form includes: a heterogeneous mixture of alfuzosin hydrochloride anhydrate, lactose monohydrate, hydroxypropylmethylcellulose, polyvinylpyrrolidone and magnesium stearate, wherein the heterogeneous mixture is heterogeneously distributed throughout the unit dosage form. A manufacturing process includes: mixing a hydrophilic polymer and alfuzosin to provide a blend; granulating the blend to provide granules; drying the granules on a dryer to provide dried granules; sizing the dried granules to provide sized granules; mixing the sized granules with a lubricant to obtain a mixture; and compressing the mixture to obtain a tablet. A method of treating benign prostatic hyperplasia, includes administering to a patient the composition or unit dosage form once a day.
    武汉市罗氏科技发展有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.luoshikg.com
    企业联系电话:18986168071;19307247857👤
    📞武汉市罗氏科技发展有限公司 ⚠️参考联系方式
    联系人:罗经理;祝经理
    电话:18986168071;19307247857
    手机:18986168071;19307247857
    传真:027-88121016;QQ1712680783
    邮箱:18986168071@163.com
    通信地址: 湖北省武汉市洪山区洪山工业园
    邮编: 430064
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:湖北省武汉市洪山区洪山工业园
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    摘要:U.S. Army Armament Research & Development Command, Chemical Systems Laboratory, NIOSH Exchange Chemicals., NX#00154
    摘要:S13 | EUCOSMETICS | Combined Inventory of Ingredients Employed in Cosmetic Products (2000) and Revised Inventory (2006) | DOI:10.5281/zenodo.2624118
    摘要:International Journal of Toxicology 29(Suppl. 2):115-132, 2010
    参考文献:10.1186/1472-6815-2-1
    摘要:Malik V, Tyagi I, Varma A, Phadke RV. Use of the direct puncture technique in management of capillaro-venous malformations: case report. BMC Ear, Nose and Throat Disorders. 2002 Mar 19;2(1):1. doi: 10.1186/1472-6815-2-1.
    参考文献:10.1007/s00383-008-2124-x
    摘要:Granata C, Oddone M, Toma P, Mattioli G. Retrograde percutaneous sclerotherapy of left idiopathic varicocele in children: results and follow-up. Pediatric Surgery International. 2008 Mar 26;24(5):583–7. doi: 10.1007/s00383-008-2124-x.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知